Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00779922

Enrollment

Registered

2008-10-24

Start date

2008-11-30

Completion date

Unknown

Last updated

2016-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Renal Function, Multiple Myeloma

Keywords

Multiple Myeloma, impaired renal function

Brief summary

The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in patients presenting with Multiple Myeloma and impaired renal function, the safety of Revlimid® in the enrolled patients population. and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.

Interventions

DRUGlenalidomide

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Documented diagnosis of relapsed or refractory multiple myeloma (MM). * Age \> 18 years at the time of signing the informed consent form * Stable renal function

Exclusion criteria

* Documented amyloidosis * Any prior use of Revlimid ® * Any contraindication to Revlimid ® and especially: * Lack of acceptable method of birth control for female of childbearing potential (FCPB) * Men who don't agree to use condom during the study and 4 weeks after the last study drug intake if their partner is a FCPB. * Pregnant or breast feeding women

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026